Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy A STROBE-compliant observational study


Esatoglu S. N. , Hatemi G. , Ugurlu S., Gokturk A., Tascilar K., Ozdogan H.

MEDICINE, vol.96, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 96 Issue: 34
  • Publication Date: 2017
  • Doi Number: 10.1097/md.0000000000007859
  • Title of Journal : MEDICINE

Abstract

There are no treatment modalities, which were proven to prevent the deposition of amyloid, proteinuria, and loss of renal function due to amyloidosis. Anti-tumor necrosis factor agents (anti-TNFs) were shown to decrease the production of serum amyloid A protein. We aimed to evaluate the long-term efficacy and safety of anti-TNFs in secondary (AA) amyloidosis patients treated in a single center.